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Eculizumab  is  a humanized  IgG2/4  chimeric  anti-complement  C5  antibody  used to  treat  patients  with
paroxysmal  nocturnal  hemoglobinuria  (PNH)  or atypical  hemolytic  uremic  syndrome.  The aim  of this
study  was  to evaluate  whether  or not  the complement  activity  in  newborns  from  pregnant  women  who
receive  eculizumab  is impaired.  A novel  eculizumab-C5  complex  (E-C5)  speciﬁc  assay  was  developed
and  revealed  that  two  newborns  carried  only  6–7%  of the  E-C5  detected  in  their  eculizumab-treated  PNH
mothers.  Serum  from  the  pregnant  women  completely  lacked  terminal  complement  pathway  activity,
whereas  the  complement  activity  in  the  serum  of  the  newborns  was  completely  normal.  Data  from  the
pregnant  women  and  their  newborns  were  compared  with  that  of  healthy  age-matched  female  controls
and  healthy  newborns,  as  well  as  a non-treated  pregnant  woman  with  PNH  and  her newborn.  Theseculizumab
aroxysmal nocturnal hemoglobinuria
all  showed  normal  complement  activity  without  detectable  E-C5  complexes.  Furthermore,  absence  of
eculizumab  or E-C5  in  the  newborn  could  not  be explained  by  lack  of  eculizumab  binding  to  the  neonatal
Fc receptor  (FcRn),  as  eculizumab  bound  strongly  to  the  receptor  in  vitro.  In conclusion,  despite  binding
to  FcRn  neither  eculizumab  nor  E-C5  accumulates  in  fetal  plasma,  and  eculizumab  treatment  during
pregnancy  does  not  impair  the  complement  function  in  the  newborn.
© 2014  The  Authors.  Published  by  Elsevier  GmbH.  This  is  an  open  access  article  under  the  CCntroduction
Complement is part of the innate immune system, recogniz-
ng microbes and thus protecting the host against invasion of
athogens. Although discovered more than hundred years ago,
s a factor in serum that induced lysis and killing of bacteria in
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the presence of antibodies, it is only during the last couple of
decades that the functional role of complement in human dis-
eases has been explored. Previously regarded as a pure defense
system, complement is now appreciated as crucially important for
tissue homeostasis by clearance mechanisms, tissue regeneration
and repair (Ricklin et al., 2010). The main effectors of complement
activation to serve these functions are induction of a number of
downstream inﬂammatory networks as well as phagocytosis and
cell lysis (Walport, 2001). Complement activation products like
the anaphylatoxins C3a and C5a are potent inﬂammatory induc-
ers (Klos et al., 2009). Assembly of the terminal C5b-9 complement
complex (TCC) on a lipid membrane leads to insertion of the
access article under the CC BY-NC-ND license (http://creativecommons.org/
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embrane attack complex (MAC), which in sublytic doses induces
nﬂammation (Morgan, 1989; Tegla et al., 2011), or in the case of
ed blood cells and neisserial bacteria leads to lysis (Bhakdi, 1991).
hen the TCC is formed in the ﬂuid phase, the soluble sC5b-9
omplex is generated, which is a useful indicator of complement
ctivation.
Complement activation is a double-edged sword. By induc-
ng inﬂammation and cell lysis as response to both microbes
nd damaged host structures, there is a potential for comple-
ent to damage self-tissue (Mollnes et al., 2002). In order to
void self-damage, there is an absolute need for strict control by
 number of ﬂuid-phase and membrane-bound regulatory pro-
eins (Meri, 2007; Sjoberg et al., 2009; Zipfel and Skerka, 2009).
any of the complement components are spontaneously acti-
ated in the absence of activating stimuli. Thus, the lack of such
 regulatory protein per se is sufﬁcient for a pathologic com-
lement activation leading to tissue damage in various disease
onditions.
Genetic deﬁciencies or mutations of regulatory proteins like
actor H, factor I and membrane cofactor protein (CD46) are asso-
iated with diseases like atypical hemolytic uremic syndrome
aHUS) (Le et al., 2010), membranoproliferative glomerulonephris-
is (MPGN) type II (dense deposits disease) (Servais et al., 2012)
nd age-related macular degeneration (Shaw et al., 2012). Parox-
smal nocturnal hemoglobinuria (PNH) is a disease characterized
y spontaneous complement-mediated red blood cell lysis due to
 somatic mutation in the PIG-A gene coding for the glycosylphos-
hatidylinositol anchor, which is required for the attachment of
omplement regulators decay accelerating factor (DAF; CD55) and
D59 (Takeda et al., 1993). The phenotype of PNH is similar to
enetic deﬁciency of CD59 (Yamashina et al., 1990), suggesting that
his protein, which protects against insertion of C8 and C9 into the
CC and, thus, against cell lysis, is crucial for the pathogenesis of
NH.
Efﬁcient therapeutic alternatives for these conditions are
imited. Eculizumab (Soliris®), a humanized IgG2/4 kappa anti-C5
ntibody is the only speciﬁc complement inhibitor approved by
he Food and Drug Administration (FDA) (Dmytrijuk et al., 2008).
t blocks the enzymatic cleavage of C5 to C5a and C5b, leaving
he initial activation of the three complement pathways up to and
ncluding C3 intact. Eculizumab is in routine clinical use on the indi-
ation of PNH and aHUS. Many years of experience have shown that
culizumab reduces the need for blood transfusions and improves
he prognosis in patients with PNH (Parker, 2009; Brodsky, 2009;
elly et al., 2011; Luzzatto et al., 2011; Roth and Duhrsen, 2011;
almeira et al., 2012; Hillmen et al., 2013; Varela, 2013; Heitlinger,
013). Recently, eculizumab was also documented to be effective
nd without adverse effects in children (Reiss et al., 2014). Thus,
reatment with eculizumab is generally safe, the main concerns
eing high costs and a small risk of neisserial infection, requiring
accination prior to treatment. Recently, it was suggested that inhi-
ition of C3 would reduce lysis more than C5 inhibition, since some
NH cells are opsonized with C3 fragments and undergo extravas-
ular hemolysis (Risitano et al., 2014). Whether C3 or C5 should be
he target for systemic complement inhibition over a long period
f time in PNH patients will depend on relative the risk of infec-
ions due to lack of C3 opsonisation of pathogens as compared to
he beneﬁt on the hemolysis.
Little is known about possible passage of eculizumab or E-C5
ver the human placenta and, consequently, how such passage
ould affect the complement system of the newborn. This is of
articular importance in PNH since without treatment, the risk of
omplications is increased for both the pregnant woman and her
hild during pregnancy and delivery (de Guibert et al., 2011). Only
 few cases have been examined with respect to the amount of free
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Kelly et al. (Kelly et al., 2010). Of four newborns from three moth-
ers with therapeutic levels, eculizumab was undetected in two and
detected in low amounts in two (twins).
There is a need for sensitive and speciﬁc methods to detect E-C5,
combined with novel functional assays for evaluation of the total
complement activity, in order to study the balance between free
eculizumab and free C5. Thus, the aims of the present study were to
establish such assays, and to investigate whether or not eculizumab
given to pregnant women  affects the complement system of the
newborn.
Methods
Patients
Three pregnant women with PNH and their newborns were
included. Two of the patients were treated with eculizumab.
Patient 1 (P1), born 1981, was  diagnosed with PNH in 2007 dur-
ing the sixth week of her ﬁrst pregnancy. Fluorescein-labeled
proaerolysin (FLAER) negative monocytes and granulocytes were
80%, lactate dehydrogenase (LD) 840 Units/L (U/L) and hemoglobin
(Hb) 11.2 g/dL. Low molecular weight heparin (LMWH) was started
as thrombosis prophylaxis. Emergency cesarean section was per-
formed at 35th gestational week due to fetal distress. The Apgar
score was 5 and placenta showed immaturity without thrombi.
During her next pregnancy in 2010, she was treated with LMWH
from week nine. FLEAR negative monocytes and granulocytes
were 91% and 94%, respectively. Hb fell gradually to 7 g/dL
and LD increased to 3300 U/L. Fatigue gradually increased. The
patient received meningococcal vaccine and was started with
eculizumab during week 34 (600 mg/week for four weeks, there-
after 900 mg  every second week). The last infusion in the pregnancy
was given six days before delivery. She improved clinically, Hb
increased to 9 g/dL and LD decreased to 300 U/L. At 41 gesta-
tional week she delivered a healthy child. Vaginal birth was
complicated by postpartum hemorrhage (the lowest postpar-
tum Hb level was  5.8 g/dL) and she received four red blood cell
units.
Patient 2 (P2), born 1986, was diagnosed with classical PNH in
2009. Initially ﬂow cytometry of red cells showed 30% CD59 neg-
ative cells (type III) and 47% type II cells. In 2012, FLAER showed
92% clone of GPI negative granulocytes. Despite chronic hemoly-
sis and LD ranging 400–600 U/L, Hb levels were close to normal
(11–12 g/dL) and she did not need any transfusions. Aspirin was
used for primary thromboprophylaxis. Her ﬁrst pregnancy resulted
in early spontaneous miscarriage at week 10 in February 2013.
Aspirin had been switched to LMWH  prophylaxis since the detec-
tion of the pregnancy. LD and Hb remained stable. She conceived
again six months later. LMWH  was used for prophylaxis and she
started with eculizumab during her second trimester in November
2013, initially dosed 600 mg  once weekly for four doses followed
by 900 mg  every two weeks. In addition to receiving meningococ-
cal vaccine prior starting eculizumab, continuous oral penicillin
prophylaxis was  also used. There were no complications during
pregnancy, Hb was 10–12 g/dL and LD decreased to normal levels.
Delivery was  electively induced due to hyperglycemia in pregnancy
week 39, April 2014. A healthy baby was delivered by emergency
cesarean section due to obstructed labor. Blood loss due to uterine
atony was  2500 mL  and the patient received two  units of PRBCs,
eight units of platelets and three units of plasma on the day of
delivery. She had received eculizumab on schedule 9 days prior to
delivery and received the next dose the day before discharge. Her
Hb was 9.6 g/dL and LD was 387 U/L at discharge. Twelve days after
discharge the patient developed uterine infection and a mesenteric
vein thrombosis was diagnosed. Prophylactic LMWH  was  increased
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o therapeutic dose with plans of long-term anticoagulation with
arfarin. Eculizumab was planned to continue for at least 3 months
ost-partum.
Patient 3 (P3) was not treated with eculizumab. She was  born
981 and diagnosed with classical PNH in 1998. Clone size from
ranulocytes has been 50–60%. She had a history of pulmonary
mbolism two years after the PNH diagnosis and warfarin anticoag-
lation was then started. She has not required transfusions, but has
een iron deﬁcient. Her obstetric history includes a spontaneous
arly miscarriage in 2008 and two prior successful pregnancies and
eliveries in 2009 and 2011, for which she required multiple red cell
ransfusions. Her most recent pregnancy was detected in July 2013.
culizumab treatment was  offered, but she declined as her Hb levels
tayed at 10–12 g/dL and there were no signs of increased hemoly-
is (LD 350–450 U/L). She received LMWH  at treatment doses. She
ad an uncomplicated vaginal term delivery of a healthy baby.
here were no signs of increased hemolysis and the puerperium
as uneventful.
lood sampling and preparation
Serum samples were obtained from P1 and P2 before starting
culizumab treatment and at delivery. Serum from P3 was obtained
uring pregnancy and at delivery. Blood samples from the umbilcal
ords were carefully obtained by needle puncture of a placental vein
o avoid contamination from mothers’ blood and Wharton’s jelly.
erum was prepared by drawing whole blood into empty tubes,
lotting was allowed for 60 min, followed by 15 min  centrifuga-
ion at 3220 × g. The samples were immediately stored in multiple
liquots at −80 ◦C and repeated thawing and freezing was avoided.
eagents
hemicals and buffers
2,2′-Azino-di(3-ethylbenzthiosoline sulphonate) (ABTS), ethyl-
ne diamine tetra-acetic acid (EDTA) and polyethylene sorbitan
onolaurate (Tween 20) were obtained from Sigma-Aldrich (St.
ouis, MO). Na2CO3·H2O, NaHCO3, KH2PO4, Na2HPO4, NaCl and
aC2H3O2 were obtained from Merck (Darmstadt, Germany).
hosphate-buffered saline (PBS) consisted of 0.068 M phosphate
uffer, pH 7.2, containing 0.077 M NaCl. Coating buffer consisted of
.05 M carbonate buffer, pH 9.6. Antigens and antibodies for ELISA
nalyses were diluted in PBS containing 0.2% Tween 20. Washing
uffer consisted of PBS containing 0.1% Tween 20. Substrate buffer
onsisted of 0.15 M sodium-acetate buffer, pH 4.0.
ntibodies and proteins
Monoclonal antibody against human C5 was  obtained from
uidel (San Diego, CA). Horseradish peroxidase (HRP)-conjugated
ouse anti-human IgG4 antibody (clone HP 6025) was obtained
rom Southern Biotech (Birmingham, AL). Eculizumab (Soliris®), a
umanized monoclonal antibody (IgG2/4) inhibiting cleavage of C5,
as obtained from Alexion Pharmaceuticals (Cheshire, CT). Puriﬁed
uman complement protein C5 was obtained from Quidel.
unctional complement activity assay
Functional complement activity was measured using the Com-
lement system Screen Wieslab® (Euro Diagnostica AB, Malmö,
weden) detecting complement activation through the classical
nd alternative pathways, with the complete terminal pathway
ctivation as readout. Thus, samples without C5 activity will give
ero % activity in this assay, due to blocking of the terminal pathway,
lthough the activity of the initial pathways up to and including C3
s intact.ology 220 (2015) 452–459
Enzyme-immunoassay for the detection of eculizumab-C5
complexes
A new sandwich ELISA to measure eculizumab-C5 (E-C5) com-
plexes was  designed by using anti-C5 and anti-IgG4 as capture and
detection antibodies, respectively, and using in vitro-generated E-
C5 complexes as standard. The standard of E-C5 complexes was
made in vitro by adding eculizumab to a normal serum pool from 20
healthy blood donors. Eculizumab was  diluted in PBS twofold in 10
steps starting at 1 mg/mL. Five L from each dilution were added to
new tubes, each containing 95 L of the standard serum pool. Opti-
mal  dilutions of the reagents in the different steps were found after
careful titration. Nunc Maxisorp® 96-wells Immunoplates (Thermo
Scientiﬁc Nunc A/S, Roskilde, Denmark) were coated overnight at
4 ◦C with a monoclonal antibody against human C5 (1.1 g/mL
in 0.05 M carbonate buffer). Standards and serum samples were
added in duplicates, diluted 1:100 in PBS containing 0.2% Tween
20 and incubated at room temperature for 60 min. Samples from
the patients receiving eculizumab needed further dilution, up to
10 times, in order to obtain absorbance values at the optimum of
the standard curve. HRP-conjugated mouse anti-human IgG4 anti-
body was diluted 1:2500 in PBS containing 0.2% Tween 20, added
to the plate and incubated at room temperature for 60 min. The
plates were automatically washed three times after each incubation
(Hydrospeed, Tecan Trading AG, Männedorf, Switzerland) using
PBS containing 0.1% Tween 20. As substrate, H2O2 was used at a
ﬁnal concentration of 2.4 × 10−3%, in 0.15 M sodium acetate buffer,
pH 4.0, containing 180 mg/L ABTS. The wells were ﬁlled with 100 L
in all steps, except for the washings steps (250 L). Optical den-
sity (OD) was  determined at 405 nm (Dynex MRXe reader, DYNEX
Technologies, Inc, Chantilly, VA, USA) when the highest standard
had reached an OD of approximately 1.0 (10–15 min).
Validity and speciﬁcity of the assay was  veriﬁed using C5 deﬁ-
cient serum reconstituted with puriﬁed C5. The reliability was
investigated by calculating inter- and intra assay variation. The
sensitivity and accuracy was examined by spiking normal human
serum as well as the patient serum samples were eculizumab (1,
10, 30 and 100 g/mL) and/or C5 protein (100 g/mL). The concen-
tration of the E-C5 complexes is given as eculizumab-equivalent
amount in g/mL.
Immunoﬁxation
The anti-kappa antibody for immunoﬁxation electrophoresis
was obtained from Sebia (Evry Cedex, France). Immunoﬁxation
electrophoresis of serum samples, eculizumab, free C5 and E-C5
complexes in PBS was  performed using a HYDRASYS Focusing elec-
trophoresis and immunoﬁxation system from Sebia (Evry Cedex,
France). Eculizumab-C5 complexes were generated in vitro by
mixing eculizumab and puriﬁed C5 at different molar ratios.
Immunoﬁxation was performed using 12 L anti-kappa antibody
and Hydragel 4 IF kits (Sebia). After electrophoresis, the gels were
stained with Coomassie brilliant blue and air-dried. The gels were
photographed using a ChemiDoc XRS+ gel imaging system with
Image Lab software from BioRad (Hercules, CA).
Enzyme-immunoassay for FcRn binding
Nunc MaxiSorp® microtiter wells were coated with titrated
amounts of eculizumab, rituximab (anti-CD20, Roche, Basel,
Switzerland) or inﬂiximab (anti-tumor necrosis factor , Janssen
Biologics, Leiden, The Netherlands) diluted to 4 g/mL in
PBS. Following incubation overnight at 4 ◦C, the plates were
blocked with 4% skimmed milk/PBS/Tween20 (S/PBS/T) for 2 h
at room temperature and washed four times in PBS/T. Recombi-
nant glutathione-S-transferase (GST)-tagged soluble human FcRn
unobiology 220 (2015) 452–459 455
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Fig. 1. Assay for quantiﬁcation of eculizumab-C5 (E-C5) complexes. (A) The standard
was made by adding eculizumab (0–100 g/mL) to a normal human serum pool.
This standard showed a dose-dependent curve read as optical density (OD) and was
used as standard curve for the assay. The amount of E-C5 complexes is indicated in
eculicumab equivalents, i.e. corresponding to the amount in g/mL of eculizumab
added per mL  of serum. Broken lines indicate lower detection limit. (B) Speciﬁcity of
the assay was examined using C5-deﬁcient serum (C5D, closed circles). Eculizumab
was added to C5D without any increase in OD. In contrast, a dose response curve
was  obtained with formation of E-C5 after reconstitution of C5D with puriﬁed C5
(C5D + C5, open circle). (C) Normal human serum was spiked with 1, 20 and 30 g
eculizumab per mL  and measured in the E-C5 assay. The obtained values corre-
sponded closely to those expected. (D) The concentration of E-C5-complexes was
133 and 115 g/mL in P1 and P2 serum (closed circles), whereas the newborns’
corresponding serum contained 8.1 and 7.8 g/mL, respectively (closed triangles).
Adult (open circles) and newborn (open triangles) control sera (n = 6 of each) did not
contain detectable E-C5 complexes, as was the case for P3 (PNH without eculizumab,
open asterisk) and her newborn (closed asterisk). Broken line indicate lower detec-R.F. Hallstensen et al. / Imm
shFcRn-GST) (Andersen et al., 2008) was diluted to 2 g/mL in
/PBS/T and incubated for 1 h prior to washing as above. Bind-
ng was detected by a HRP-conjugated goat anti-GST antibody
GE Healthcare, Oslo, Norway). Plates were developed by adding
,3′,5,5′-Tetramethylbenzidine substrate (Calbiochem, San Diego,
A) and the reaction was terminated by addition of 100 L 1 M
Cl. Absorbance was measured at 450 nm using a Sunrise TECAN
pectrophotometer (Tecan Trading AG, Männedorf, Switzerland).
tatistics
Student’s t-test was used to compare the complement activ-
ty in eculizumab-treated patients and their newborns with the
espective controls.
thics
The study was approved by the regional ethical committees.
ritten informed consent was obtained from the patients and con-
rols.
esults
 novel assay for quantiﬁcation of eculizumab-C5 (E-C5)
omplexes in human serum
ssay design, reliability and validity
The E-C5 assay was  designed as a double-antibody enzyme-
mmunoassay using an anti-C5 antibody for capture and an
nti-IgG4 antibody for detection. An E-C5 standard was  produced
y adding eculizumab to a normal human serum pool, and the
tandard curve was designed by two-fold dilution starting at
00 g/mL (Fig. 1A). The amounts of E-C5 are given in eculizumab-
quivalents, i.e. 1 g/mL E-C5 corresponds to 1 g eculizumab
dded to 1 mL  of serum. The lower detection limit (deﬁned as back-
round + 2 SD) was approximately 1 g/mL (Fig. 1A). The intra- and
nter-assay coefﬁcients of variation were 8.9% and 4.9%, respec-
ively.
The assay detected E-C5 in human serum with high speciﬁcity
s demonstrated using serum from a genetic C5-deﬁcient individ-
al (Lappegard et al., 2009) with and without addition of puriﬁed
5 (Fig. 1B). No signal was detected upon addition of up to 100 g
culizumab/mL to C5-deﬁcient serum, whereas E-C5 was detected
n a dose-dependent manner after reconstitution of the deﬁcient
erum with C5. During spiking experiments using normal human
era, the amounts of E-C5 detected corresponded exactly to the
xogenously added 1, 10 and 30 g eculizumab per mL  serum
Fig. 1C). This indicates that there was no interference in the assay.
-C5 complexes in human serum samples
Serum samples were added in optimal dilutions (see Section
Methods”) and the results were corrected for the dilution to give
he E-C5 concentration in undiluted serum (Fig. 1D). Using this
ssay, 133 g/mL and 115 g/mL of E-C5 were detected in serum
rom two eculizumab treated mothers (P1 and P2). In contrast, only
.1 g/mL and 7.8 g/mL were detected in their newborns, corre-
ponding to 6–7% of that in the mothers’ sera. In control sera (n = 6
or adults and newborns) and in the serum of a non-eculizumab-
reated PNH patient (P3) and her newborn, E-C5 was not detected
Fig. 1D).
ffect of eculizumab on functional complement activityssay for functional complement activity
Serum samples from the eculizumab-treated PNH mothers
P1 and P2) and their newborns, as well as from the controls,tion limit.
were examined in the Total Complement Functional Screen ELISA
(Wieslab®), which is superior to the traditional CH50 based on red
cell lysis with respect to sensitivity and reproducibility (Seelen
et al., 2005). The assay speciﬁcally detects complement activity
of the three initial pathways using terminal assembly of C5b-9
as readout. Thus, complete inhibition of C5 would abolish activ-
ity of the terminal pathway irrespective of which pathway that
is initially activated, whereas the initial pathway activation up
to and including C3 is intact. We  here used the classical path-
way (CP) and alternative pathway (AP) assays for evaluation of
their suitability for evaluation of eculizumab. Serum from P1
and P2 had no detectable activity in CP and AP (Fig. 2A), con-
sistent with complete inhibition of C5. The six healthy controls
and P3 showed normal complement activity (signiﬁcant differ-
ence between P1 and P2 versus controls: p < 0.0001 for CP and
p = 0.018 for AP). Serum from the newborns of P1 and P2 showed
completely normal complement activity (Fig. 2B), with no sig-
niﬁcant difference from the controls (p = 0.54 for CP and p = 0.30
for AP).
456 R.F. Hallstensen et al. / Immunobiology 220 (2015) 452–459
Fig. 2. Complement functional activity. (A) Serum complement activity was  mea-
sured in P1 and P2 at delivery (closed circles), in six healthy controls (open circles) as
well as in P3 at delivery (PNH without eculizumab, open asterisk) in the classical (CP)
and alternative (AP) pathways. Consistent with full inhibitory effect on the terminal
pathway by eculizumab, there was no activity in the P1 and P2 sera. Horizontal lines
indicate lover reference values. (B) Newborns have lower complement activity and
greater range than adults (cfr. scale on y-axis) and reference ranges for the func-
tional assay is not established. The newborns of P1 and P2 showed high activity in
both pathways (closed triangles), consistent with a fully active complement system.
Controls include healthy normal newborns (open triangels) and newborn from P3
(PNH without eculizumab, closed asterisk). (C) Effect of adding C5 in increasing con-
centrations on serum functional activity of the terminal pathway measured by the
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Fig. 3. Complement activity in titrated sera. (A and B) Serum from P1 and P2 at
delivery (pregnant women  with eculizumab, closed circles) and serum from two
healthy controls (open circles) were titrated in the functional complement assay. (C
and  D) Serum from the newborns of P1 and P2 (closed triangles) and sera from twolassical pathway assay from a normal adult serum (open circles) and serum from
1.  (D) Same experiment as described in panel C, using serum from a normal healthy
ewborn (open triangles) and serum from the newborn of P1 (closed triangles).
ffect of addition of C5 to the serum on functional complement
ctivity
The effect of adding increasing amounts of puriﬁed C5 to the
erum was studied using the CP assay. The average normal serum
oncentration in adults is 75 g/mL. Addition of 1 mg/mL of C5 to
erum from P1 restored functional complement activity (Fig. 2C),
hereas no additional complement activity was observed in serum
rom her newborn (Fig. 2D), suggesting efﬁcient suppression of C5
nd the presence of free eculizumab in the mother, but no free
culizumab available for C5 suppression in her newborn.
ffect of eculizumab on functional complement activity in titrated
era
itration of sera in the functional assay
Since the functional complement activity examined in the
xperiments presented in Fig. 2 was measured as end-point at a
xed dilution of the serum, we investigated the effect of eculizumab
n the complement activity over a long dilution range (Fig. 3).
y using both CP (Fig. 3A) and AP (Fig. 3B) the terminal path-
ay activation was completely abolished in P1 and P2 regardless
f the dilution, whereas complement activity in the healthy con-
rols decreased in accordance with titration. Notably, the newborns
rom P1 and P2 showed a similar decrease in terminal pathwayhealthy newborns were titrated in the functional complement assay. CP, classical
pathway; AP, alternative pathway.
activity as their controls as measured by the CP (Fig. 3C) and AP
(Fig. 3D). Collectively, these data demonstrate that the newborns
from eculizumab treated mothers had completely normal comple-
ment activity independent of serum dilution.
Detection of E-C5 in serum from P1 and her newborn with and
without substitution with eculizumab or C5
In order to control for sufﬁcient therapeutic C5 inhibition in the
eculizumab-treated mother and free C5 in her newborn, the pres-
ence of E-C5 was  measured in serum from P1 and her newborn
before and after addition of eculizumab or C5 (Fig. 4). Consistently,
the E-C5 concentration in P1 was unaffected by the addition of
eculizumab or C5 (Fig. 4A). Addition of eculizumab to the P1 new-
born serum substantially increased the E-C5 levels, consistent with
binding of eculizumab to free C5 (Fig. 4B).
Visualization of eculizumab, C5 and E-C5 in serum samples from
P1 and her newborn by immunoﬁxation
Detection of puriﬁed C5, eculizumab and E-C5 by agarose gel
electrophoresis and immunoﬁxation
Puriﬁed E-C5 was identiﬁed by protein staining (Fig. 4D, lane
1) and compared to IgGK)-speciﬁc immunoﬁxation using different
molar ratios between C5 and eculizumab (Fig. 4C, lanes 2–6). The
anti-kappa antibody speciﬁcally detects free eculizumab (IgG2/4 )K
and E-C5. When E-C5 was  formed in the presence of an excess of
free eculizumab, the latter appears in a lower molecular weight
band (Fig. 4C, lanes 2–4), which corresponds to the band observed
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Fig. 4. Effect of adding eculizumab and C5 to the sera and detection of E-C5 in
mother’s serum using immunoﬁxation electrophoresis. (A) E-C5 complexes were
measured in P1 serum (PBS) and in P1 serum to which was  added eculizumab (E)
or  puriﬁed C5 (C5) (mean with range of n = 3). (B) Same experiment as described
in  panel A, but using serum from the newborn of P1 (mean with range of n = 3).
(C)  Lanes 1 and 7 represent protein staining with Coomassie brilliant blue (CB) in
electrophoresis, identifying the lines for puriﬁed E-C5 and puriﬁed C5, respectively.
Lanes 2–6 and 8–12 represent immunoﬁxation based on an antibody reacting with
the kappa-chain (eculizumab has kappa light chains). Lane 12 identiﬁes eculizumab
alone. Lanes 2–6 shows EC-C5 complexes made in vitro and titrated from the left
(eculizumab in excess) to the right (C5 in excess). Lane 8: Serum from P1. Lane
9
b
i
a
i
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n
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f
d
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e
s
e
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t
m
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e
I:  Serum from P1’s newborn. Lane 10: normal adult serum. Lane 11:  normal new-
orn serum. Solid horizontal line: indicating position of C5. Broken horizontal line:
ndicating position of eculizumab. E-C5 complexes appear between the lines.
fter addition of eculizumab alone (lane 12). Puriﬁed free C5 was
dentiﬁed by protein staining (Fig. 4C, lane 7).
etection of E-C5 complexes in serum samples from P1 and her
ewborn
The immunoﬁxation revealed a distinct band in the serum from
1 (Fig. 4C, lane 8), corresponding to E-C5, while no such band was
bserved in serum from her newborn (lane 9). Also, serum samples
rom both a healthy adult control and a healthy newborn control
id not contain detectable E-C5 (Fig. 4C, lanes 11 and 12).
inding of FcRn to eculizumab
The therapeutic effect of IgG antibodies is dependent on their
ong serum half-life, which is regulated by FcRn-mediated recycling
n endothelial and hematopoietic cells (Montoyo et al., 2009; Wani
t al., 2006). Speciﬁcally, IgG binds FcRn within acidiﬁed endo-
omes that are subsequently recycled to the cell surface where
xposure to the neutral pH of the blood triggers release of IgG
Ward, 2009; Roopenian and Akilesh, 2007). Thus, FcRn rescues
gG from intracellular degradation and extends its half-life. In addi-
ion, FcRn provides passive immunity to the fetus by transcytosing
aternally-derived IgG across the placenta (Firan et al., 2001;
athiesen et al., 2013). To address whether the humanized IgG2/4K
culizumab binds human FcRn with the same strength as human
gG1, we performed an ELISA where pH dependent binding to FcRnFig. 5. Effect of pH on eculizumab binding to FcRn. ELISA binding responses of
titrated amounts of eculizumab, inﬂiximab and rituximab to GST-tagged hFcRn at
pH  6.0 (A) and pH 7.4 (B). The data represents the mean of duplicates.
was compared with that of rituximab (chimeric IgG1K) and inﬂix-
imab (chimeric IgG1K). Titrated amounts of the antibodies were
coated in wells followed by addition of GST-tagged shFcRn at either
pH 6.0 (Fig. 5A) or pH 7.4 (Fig. 5B). Eculizumab was shown to bind
the receptor equally well as rituximab and inﬂiximab, in a pH-
dependent manner, with strong binding at pH 6.0 and no binding at
neutral pH. Thus, the absence of eculizumab in fetal plasma cannot
be explained by reduced binding to FcRn.
Discussion
We have here described a comprehensive set of experiments
documenting the reliability and validity of a novel assay for detec-
tion of complexes between eculizumab and C5. Using this assay,
as well as functional complement activity assays and immunoﬁx-
ation, we reveal that there is very little eculizumab as well as
E-C5 in the serum of newborns of pregnant women treated with
eculizumab. Consequently, the newborns have a fully functional
complement system. The importance of the data is emphasized by
the increasing number of pregnant women who  are candidates for
eculizumab treatment. PNH is the disease where most pregnant
patients have been treated with eculizumab (de Guibert et al., 2011;
Kelly et al., 2010; Danilov et al., 2010; Marasca et al., 2010), but
there are also reports for aHUS and preeclampsia (Ardissino et al.,
2013; Canigral et al., 2014; Burwick, 2012). Other conditions, in
which pregnancy is an option, will likely come up in the future as
candidates for complement inhibition, like the anti-phospholipid
syndrome (Erkan et al., 2014). The safety of treatment and effect on
the newborn will, however, be a main concern. Despite a limited
number of patients available for the present study, robust meth-
ods were established and used to document that treatment with
eculizumab during pregnancy would be of minor risk to the new-
born. This could be individually evaluated in the future using the
set of analyses presented here.
The amount of E-C5, complement blockage and complement
activity in the newborn have to our knowledge not previously been
described. In one review on seven pregnant patients receiving
eculizumab during pregnancy, eculizumab was quantiﬁed in cord
blood from four newborns (Kelly et al., 2010). In two, eculizumab
was undetectable and in two (twins, cesarean section at week
35 of gestation) low levels were found, which according to the
authors, “were within the background levels for the assay and
insufﬁcient to block complement”. The pregnant women had ther-
apeutic levels of eculizumab in their serum. Traditional hemolytic
assays were used for evaluation of the complement activity. These
assays do not have the same sensitivity and reliability as the
novel assays recently used to evaluate aHUS patients treated with
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culizumab (Cugno et al., 2014; Noris et al., 2014). Using these
obust ELISA-based assays for complement activity and the novel
-C5 assay developed in the present study, we consistently show
hat eculizumab in therapeutic doses in the pregnant women  did
ot affect the complement system of their newborn.
The E-C5 assay we describe was documented to be highly spe-
iﬁc and sensitive. Thus, the reactivity was nil in serum from
 genetic C5-deﬁcient individual, even when eculizumab was
dded to high concentrations. Addition of puriﬁed C5 to the C5-
eﬁcient serum restored a dose-dependent increase in E-C5. The
ensitivity limit in serum was found to be below 1 g/mL added
culizumab, which equals less than 1% of the amount detected in
he patients treated with eculizumab. The E-C5 levels in the new-
orns, 7–8 g/mL, were detected three titer steps above the lower
etection limit, and were thus highly reliable.
Eculizumab is a humanized IgG2/4K hybrid antibody aimed at
inimizing the effector functions mediated by complement acti-
ation and Fc  receptor engagement, as previously demonstrated
Lau et al., 2013). While the binding activity toward the classical Fc
eceptors are lacking or low, eculizumab binds the non-classical Fc
eceptor FcRn in a strictly pH dependent manner, similar to that
f two commercially available human IgG1K antibodies, inﬂiximab
nd rituximab. This is as expected since binding to FcRn is depend-
nt on two histidine residues (His310 and His435) at the CH2-CH3
lbow region, which are conserved in all subclasses except IgG3,
hich has Arg435 (Ward, 2009; Roopenian and Akilesh, 2007). FcRn
s a homeostatic regulator of IgG, and hence responsible for the
-week long half-life of endogenous IgG. However, the serum half-
ife of therapeutic IgG antibodies varies, and previous studies have
hown the half-life of eculizumab, inﬂiximab and rituximab to be
1.3, 9.5 and 22 days, respectively, the latter two being chimeric
gG1K antibodies that cross the placenta and are found in the serum
f the newborn (Malek et al., 1996; Kane, 2009; Regazzi et al., 2005;
link et al., 2008; McKeage, 2011). As we here demonstrate that
hese three antibodies bind FcRn with equal binding strength, it
xplains their prolonged half-life, but not why they show differ-
nt serum persistence in general and possibly different placental
ransfer and/or fetal serum persistence. The differences may  be
elated to the amounts of therapeutic antibody given as well as the
oncentration, biophysical properties and biodistribution of their
espective antigens. Furthermore, it could be due to differences in
ow the antibodies are transported and sorted by FcRn when bound
o their cognate antigens. As the antigens for eculizumab and inﬂix-
mab are both soluble with only one antibody binding site, these
omplexes should not cross-bind classical Fc  receptors, which is
 prerequisite for removal by phagocytosis.
The four human IgG subclasses are all actively transported
cross the placenta, and whereas IgG1, IgG3 and IgG4 are detected
n the fetus in amounts similar to those found in the mother, IgG2
s detected in lower amounts (Palmeira et al., 2012; Hashira et al.,
000). It is generally accepted that FcRn plays a key role in shutt-
ing of IgG to the fetus as substitution of the amino acids that are
irectly involved in FcRn, but not classical Fc  receptor binding,
bolishes transplacental transport in ex vivo perfusion model sys-
ems (Palmeira et al., 2012; Firan et al., 2001; Mathiesen et al.,
013). However, the reason why IgG2 is found in lower amounts
s still not known. In this study, we demonstrate that very small
mounts of the IgG2/4 chimeric eculizumab can be detected in
he newborn. Still, eculizumab may  well be transported across the
lacenta, and the observed low steady state level due to the rela-
ive rates of transport and clearance. This needs to be addressed in
uture studies.Furthermore, the E-C5 detected in the serum of the newborn
ould be formed either after passage of eculizumab, or could be the
esult of E-C5 passage. We  examined E-C5 concentration and com-
lement activity in the serum from P1 in detail, also after additionology 220 (2015) 452–459
of puriﬁed C5. Normal physiological C5 concentration in adults is
75 g/mL. Since full complement activity was  obtained only after
addition of at least 1 mg/mL  C5, eculizumab was present in excess in
the serum of the mother, consistent with the sample being obtained
six days after an eculizumab infusion. Thus, our data show that both
free eculizumab as well as E-C5 is present in mother, and available
for transport to the newborn.
In conclusion, our data indicate no adverse effects of the
eculizumab treatment of the pregnant women on the complement
activity of her newborn. Thus, our study suggests that eculizumab
should be regarded as safe with respect to the defense system of the
newborn. We  suggest that the combination of methods described
in the present study is particularly suitable for further investigation
of pregnant patients treated with eculizumab and their newborns.
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